Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Former Chief Medical Officer | March 04, 2026 | March 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date March 04, 2026 · Filed March 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 102,979 |
Reported balance
After 2026-03-04 transaction · row 1
1 source rowRow 1 · 2026-03-04 · Sale · Disposed 1,100 · Balance 102,979 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2026 Filed Mar 5, 2026 21:33 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,100 | $13.31 | $14,635.94 |
DisclosureSEC source: 0002007766-26-000003 · primarydocument.xml · nonDerivative · entry 1 Leupin Nicolas · CIK 0002007766 · Former Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,979 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:09 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,029 | $13.66 | $14,060.05 |
DisclosureSEC source: 0002007766-26-000002 · primarydocument.xml · nonDerivative · entry 1 Leupin Nicolas · CIK 0002007766 · Former Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,079 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.45 USD to $13.97 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:42 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Options (Right to buy) · Derivative | 81,499 | $18.19 Strike: $18.19 | $1,482,466.81 |
DisclosureSEC source: 0001562180-25-002163 · primarydocument.xml · derivative · entry 2 Leupin Nicolas · CIK 0002007766 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,499 Underlying: Ordinary Shares · 81,499 shares Expires 2035-03-03 F2 · derivative.exercise_date: Options to buy 81,499 ordinary shares will vest in equal installments on each of March 4, 2026, 2027, 2028 and 2029, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:42 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 54,975 | $18.19 | $999,995.25 |
DisclosureSEC source: 0001562180-25-002163 · primarydocument.xml · nonDerivative · entry 1 Leupin Nicolas · CIK 0002007766 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,108 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on March 4, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 02:26 UTC Amendment | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 161 | $20.55 | $3,308.39 |
DisclosureSEC source: 0001562180-25-001913 · primarydocument.xml · nonDerivative · entry 2 Leupin Nicolas · CIK 0002007766 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,133 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: On the transaction date, the reporting person sold 161 shares in multiple trades at prices ranging from $20.41 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 02:26 UTC Amendment | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 830 | $19.92 | $16,535.18 |
DisclosureSEC source: 0001562180-25-001913 · primarydocument.xml · nonDerivative · entry 1 Leupin Nicolas · CIK 0002007766 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,294 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: On February 27, 2025, the reporting person sold 830 shares in multiple trades at prices ranging from $19.41 to $20.4033. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:28 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 161 | $20.55 | $3,308.39 |
DisclosureSEC source: 0001562180-25-001836 · primarydocument.xml · nonDerivative · entry 2 Leupin Nicolas · CIK 0002007766 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,133 F2 · price: On February 27, 2025, the reporting person sold 161 shares in multiple trades at prices ranging from $20.41 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:28 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 830 | $19.92 | $16,535.18 |
DisclosureSEC source: 0001562180-25-001836 · primarydocument.xml · nonDerivative · entry 1 Leupin Nicolas · CIK 0002007766 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,294 F1 · price: On February 27, 2025, the reporting person sold 830 shares in multiple trades at prices ranging from $19.41 to $20.4033. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:33 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Options (Right to buy) · Derivative | 78,174 | $16.30 Strike: $16.30 | $1,274,236.20 |
DisclosureSEC source: 0001562180-24-001985 · primarydocument.xml · derivative · entry 2 Leupin Nicolas · CIK 0002007766 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,174 Underlying: Ordinary Shares · 78,174 shares Expires 2034-02-26 F2 · derivative.exercise_date: Options to buy 78,174 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:33 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 51,124 | $16.30 | $833,321.20 |
DisclosureSEC source: 0001562180-24-001985 · primarydocument.xml · nonDerivative · entry 1 Leupin Nicolas · CIK 0002007766 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,124 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.